Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab
(Avastin) and erlotinib hydrochloride (Tarceva) that can be given in combination with
standard radiation therapy and capecitabine before surgery to patients with rectal cancer.
The safety and effectiveness of this combination of therapies will also be studied.
The goal of this Phase I trial was to determine the maximal tolerated dose (MTD) of
concurrent capecitabine, bevacizumab and erlotinib with preoperative radiation therapy (RT)
for rectal cancer. The trial completed as Phase I without progressing to the Phase II
portion.